Skip to main content
Erschienen in: Inflammopharmacology 6/2023

17.10.2023 | Short Communication

The effect of probiotics on the risk of mortality in patients with COVID-19: systematic review and meta-analysis of randomized trials

verfasst von: Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

Erschienen in: Inflammopharmacology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Probiotics have been hypothesized to play a beneficial role in modulating immune responses and gut microbiota in various clinical settings. This systematic review and meta-analysis aimed to assess the effectiveness of probiotics in reducing all-cause mortality among patients diagnosed with COVID-19. We conducted a comprehensive search of the following databases: PubMed, Scopus, and Web of Science for published studies, and medRxiv, Research Square, and SSRN for preprints. The search spanned from the inception of these databases to April 4, 2023. We included studies that investigated the use of probiotics as an intervention and their impact on all-cause mortality in patients with COVID-19. A random-effects model meta-analysis was employed to estimate the pooled odds ratio, along with 95% confidence interval, to quantify the outcomes associated with probiotic use compared to other interventions. Our systematic review comprised six studies, encompassing a total of 642 patients. The meta-analysis, employing a random-effects model, demonstrated a statistically significant reduction in the risk of all-cause mortality when probiotics were administered to patients with COVID-19, compared to those not receiving probiotics (pooled odds ratio = 0.44; 95% confidence interval 0.24–0.82). In conclusion, evidence derived from randomized controlled trials (RCTs) indicates a survival benefit associated with the use of probiotics among COVID-19 patients. However, it is essential to exercise caution and await data from large-scale randomized trials to definitively confirm the mortality benefits of probiotics in this patient population.
Literatur
Zurück zum Zitat d’Ettorre G, Ceccarelli G, Marazzato M et al (2020) Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med (lausanne) 7:389CrossRefPubMed d’Ettorre G, Ceccarelli G, Marazzato M et al (2020) Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med (lausanne) 7:389CrossRefPubMed
Zurück zum Zitat Di Pierro F, Iqtadar S, Mumtaz SU, Bertuccioli A, Recchia M, Zerbinati N, Khan A (2022) Clinical effects of Streptococcus salivarius K12 in hospitalized COVID-19 patients: results of a preliminary study. Microorganisms 10(10):1926CrossRefPubMedPubMedCentral Di Pierro F, Iqtadar S, Mumtaz SU, Bertuccioli A, Recchia M, Zerbinati N, Khan A (2022) Clinical effects of Streptococcus salivarius K12 in hospitalized COVID-19 patients: results of a preliminary study. Microorganisms 10(10):1926CrossRefPubMedPubMedCentral
Zurück zum Zitat Erol I, Kotil SE, Fidan O, Yetiman AE, Durdagi S, Ortakci F (2023) In silico analysis of bacteriocins from lactic acid bacteria against SARS-CoV-2. Probiot Antimicrob Proteins 15(1):17–29CrossRef Erol I, Kotil SE, Fidan O, Yetiman AE, Durdagi S, Ortakci F (2023) In silico analysis of bacteriocins from lactic acid bacteria against SARS-CoV-2. Probiot Antimicrob Proteins 15(1):17–29CrossRef
Zurück zum Zitat Ivashkin V, Fomin V, Moiseev S, Brovko M, Maslennikov R, Ulyanin A, Sholomova V, Vasilyeva M, Trush E, Shifrin O, Poluektova E (2021) Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiot Antimicrob Proteins 15(3):460–468CrossRef Ivashkin V, Fomin V, Moiseev S, Brovko M, Maslennikov R, Ulyanin A, Sholomova V, Vasilyeva M, Trush E, Shifrin O, Poluektova E (2021) Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiot Antimicrob Proteins 15(3):460–468CrossRef
Zurück zum Zitat Kasti AN, Synodinou KD, Pyrousis IA, Nikolaki MD, Triantafyllou KD (2021) Probiotics regulating inflammation via NLRP3 inflammasome modulation: a potential therapeutic approach for COVID-19. Microorganisms 9(11):2376CrossRefPubMedPubMedCentral Kasti AN, Synodinou KD, Pyrousis IA, Nikolaki MD, Triantafyllou KD (2021) Probiotics regulating inflammation via NLRP3 inflammasome modulation: a potential therapeutic approach for COVID-19. Microorganisms 9(11):2376CrossRefPubMedPubMedCentral
Zurück zum Zitat Leal-Martínez F, Abarca-Bernal L, García-Pérez A et al (2022) Effect of a nutritional support system to increase survival and reduce mortality in patients with COVID-19 in stage iii and comorbidities: a blinded randomized controlled clinical trial. Int J Environ Res Public Health 19(3):1172CrossRefPubMedPubMedCentral Leal-Martínez F, Abarca-Bernal L, García-Pérez A et al (2022) Effect of a nutritional support system to increase survival and reduce mortality in patients with COVID-19 in stage iii and comorbidities: a blinded randomized controlled clinical trial. Int J Environ Res Public Health 19(3):1172CrossRefPubMedPubMedCentral
Zurück zum Zitat Nayebi A, Navashenaq JG, Soleimani D, Nachvak SM (2022) Probiotic supplementation: a prospective approach in the treatment of COVID-19. Nutr Health 28(2):163–175CrossRefPubMedPubMedCentral Nayebi A, Navashenaq JG, Soleimani D, Nachvak SM (2022) Probiotic supplementation: a prospective approach in the treatment of COVID-19. Nutr Health 28(2):163–175CrossRefPubMedPubMedCentral
Zurück zum Zitat Reino-Gelardo S, Palop-Cervera M, Aparisi-Valero N et al (2023) Effect of an immune-boosting, antioxidant and anti-inflammatory food supplement in hospitalized COVID-19 patients: a prospective randomized pilot study. Nutrients 15(7):1736CrossRefPubMedPubMedCentral Reino-Gelardo S, Palop-Cervera M, Aparisi-Valero N et al (2023) Effect of an immune-boosting, antioxidant and anti-inflammatory food supplement in hospitalized COVID-19 patients: a prospective randomized pilot study. Nutrients 15(7):1736CrossRefPubMedPubMedCentral
Zurück zum Zitat Saviano A, Potenza A, Siciliano V et al (2022) COVID-19 pneumonia and gut inflammation: the role of a mix of three probiotic strains in reducing inflammatory markers and need for oxygen support. J Clin Med 11(13):3758CrossRefPubMedPubMedCentral Saviano A, Potenza A, Siciliano V et al (2022) COVID-19 pneumonia and gut inflammation: the role of a mix of three probiotic strains in reducing inflammatory markers and need for oxygen support. J Clin Med 11(13):3758CrossRefPubMedPubMedCentral
Zurück zum Zitat Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ 366:l4898CrossRefPubMed Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ 366:l4898CrossRefPubMed
Zurück zum Zitat Synodinou KD, Nikolaki MD, Triantafyllou K, Kasti AN (2022) Immunomodulatory effects of probiotics on COVID-19 infection by targeting the gut-lung axis microbial cross-talk. Microorganisms 10(9):1764CrossRefPubMedPubMedCentral Synodinou KD, Nikolaki MD, Triantafyllou K, Kasti AN (2022) Immunomodulatory effects of probiotics on COVID-19 infection by targeting the gut-lung axis microbial cross-talk. Microorganisms 10(9):1764CrossRefPubMedPubMedCentral
Metadaten
Titel
The effect of probiotics on the risk of mortality in patients with COVID-19: systematic review and meta-analysis of randomized trials
verfasst von
Chia Siang Kow
Dinesh Sangarran Ramachandram
Syed Shahzad Hasan
Publikationsdatum
17.10.2023
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 6/2023
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01358-y

Weitere Artikel der Ausgabe 6/2023

Inflammopharmacology 6/2023 Zur Ausgabe